# Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

> **NCT07154706** · PHASE3 · RECRUITING · sponsor: **Nuvation Bio Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Taletrectinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07154706
- **Lead sponsor:** Nuvation Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-21
- **Primary completion:** 2030-08-30
- **Final completion:** 2033-08-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07154706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07154706, "Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07154706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*